Integrating Optical Imaging and Single-Cell Spatial Omics to Uncover Biomarkers of Vitiligo Repigmentation

Grantee: Kavita Sarin, Professor, Board of Trustees of the Leland Stanford Junior University, United States

Amount: DKK 4,775,516

Grant category: Research Grants

Year: 2026

Geography: USA

Vitiligo is a skin condition caused by the progressive loss of pigment cells, leading to white patches on the skin. The condition becomes active and detectable at a cellular level long before visible skin changes are observed. However, current methods to detect such cellular-level damage require invasive biopsies. Our project will enable preventative treatments and monitoring using a noninvasive imaging tool. By combining optical imaging with spatial omics, we will develop the first cellular-level map of vitiligo without the need for biopsies. This innovative tool will use artificial intelligence to identify specific cell types and monitor disease progression in real time. This approach promises to enhance early detection and treatment of vitiligo and has potential applications for various other skin conditions, such as inflammation and cancer. Ultimately, this could lead to more personalized and effective treatments, improving patient outcomes and accelerating drug development.

WARS1–TLR4 signaling links interferon priming to UV-induced myeloid activation in photosensitive skin

Grantee: Manuel Garber, Professor, University of Massachusetts Medical School, United States

Amount: DKK 3,951,363

Grant category: Research Grants

Year: 2026

Geography: USA

Cutaneous lupus erythematosus (CLE) is a skin disease in which sunlight, instead of calming the immune system, triggers painful and damaging inflammation. This unusual reaction is poorly understood, making it difficult to prevent disease flares.
Our research has identified a group of immune cells in the skin that become highly inflammatory after sun exposure and drive tissue damage. However, the signal that activates these cells remains unknown.
We propose that a stress-related protein released by skin cells after UV exposure acts as a trigger that turns these immune cells into harmful inflammatory cells. To test this, we will study human skin samples and examine how blocking or adding this signal affects immune activation.
Understanding this mechanism could lead to new strategies to prevent sun-induced flares in lupus and related diseases.

Leveraging Demodex mites to decode inflammatory mechanisms in skin diseases

Grantee: Roberto Ricardo-Gonzalez, Associate Professor, The Regents of The University of California San Francisco, United States

Amount: DKK 3,999,258

Grant category: Research Grants

Year: 2026

Geography: USA

Demodex mites usually live harmlessly and at low levels in facial hair follicles and sebaceous glands. Still, in some people, they become overabundant and are linked to chronic inflammatory skin diseases such as rosacea. The key problem is understanding why the immune system sometimes tolerates these mites and other times triggers persistent inflammation. Our research aims to identify the molecular “switch” that determines this outcome. Using a mouse model of Demodex infection and novel Demodex-keratinocyte co-culture systems, we discovered that a signaling pathway involving IL-36 and gasdermin proteins activates protective type 2 immune cells that control mites. However, when dysregulated, this same pathway may drive excessive inflammation. By defining how skin cells sense Demodex and regulate immune responses, we aim to uncover new, targeted treatments for rosacea and other inflammatory skin conditions linked to microbial imbalance.

Ancestry-Linked IL1A Variant at 2q13 as a Driver of Keratinocyte IL‑1 Signaling and Skin Inflammation

Grantee: Lam Tsoi, Associate Professor, University of Michigan, United States

Amount: DKK 4,046,399

Grant category: Research Grants

Year: 2026

Geography: USA

Inflammatory skin diseases can be more common and severe in people of African ancestry, but the biological reasons are unknown. Our work shows that healthy skin from individuals of African ancestry has elevated interleukin 1 (IL 1) signaling, and that a specific DNA region regulating this pathway carries a variant with higher frequency among individuals of African ancestry. This project will provide mechanistic understanding of how this genetic difference changes the way skin cells sense and respond to IL 1 signaling. We will edit the variant in human skin cells and read out the effects at single cell resolution, both in the lab and in donated skin samples. By revealing how inherited differences in skin regulation drive susceptibility to inflammation, the project will lay the groundwork for ancestry aware, more precise treatments that better control disease and help reduce inequities in skin health.

Rational Design of Dual PDE4/JAK Inhibitors with Reduced Blood-Brain Barrier Penetration for Treatment of Inflammatory Skin Diseases

Grantee: Christopher Bunick, Associate Professor of Dermatology, Yale University, United States

Amount: DKK 3,751,536

Grant category: Research Grants

Year: 2026

Geography: USA

Many skin conditions like eczema, psoriasis, and hair loss are caused by an overactive immune system. Two types of medications, PDE4 inhibitors and JAK inhibitors, can calm this immune response, but each has drawbacks. PDE4 inhibitors can cause nausea and headaches because they enter the brain, while JAK inhibitors may increase infection risk. Our research asks: what if we combine both medications at lower doses? This could provide better, synergistic treatment with fewer side effects. Building on our previous work understanding how these drugs work at the molecular level, we will use artificial intelligence and computer simulations to: (1) predict which drug modifications prevent brain entry; (2) find the best drug combinations; and (3) design new, safer medications. We expect this research could lead to more effective treatments for many people with inflammatory skin diseases, with fewer side effects than current options, improving the patient standard of care.

Modeling and targeting bullous pemphigoid in skin organoids

Grantee: Karl Koehler, Associate Professor of Otolaryngology-Head and Neck Surgery, The Childrens Hospital Corporation (d/b/a Boston Children's Hospital), United States

Amount: DKK 3,998,920

Grant category: Research Grants

Year: 2026

Geography: USA

Bullous pemphigoid (BP) is a skin disease in which the immune system attacks a protein called BP180 that helps hold the layers of the skin together. This causes itching, inflammation, and blistering, mainly in older adults. BP is becoming more common as the population ages, and it is still associated with a relatively high risk of death, showing the need for better treatments.

Research has been limited because current BP models are not close to real human skin. In this project, we will use human stem cells to grow miniature skin tissues, called skin organoids, that mimic key features of human skin. We will expose these organoids to disease-causing BP antibodies to study how skin damage begins, how the skin becomes fragile, and how the immune reaction develops. This work will improve our understanding of BP, reveal possible treatment targets, and create a new human model for developing and testing future therapies.

The ISID-LEO Foundation Award 2026 – Region Americas

Grantee: Sakeen Kashem, M.D., PhD, Assistant Professor, Department of Dermatology, University of California, San Francisco, USA

Amount: USD 100,000

Grant category: LEO Foundation Awards

Year: 2026

Geography: USA

Dr. Sakeen Kashem is an Assistant Professor in the Department of Dermatology at the University of California, San Francisco.

He received the prestigious ISID-LEO Foundation Award in Region Americas during the SID annual meeting in Chicago. The award recognizes Dr. Sakeen Kashem for his exceptional research record and innovative contributions at the intersection of neuroimmunology and dermatology.

The ISID-LEO Foundation Award – worth USD 100,000 – recognizes outstanding young researchers and scientists from around the world whose work represents an extraordinary contribution to skin research and has the potential to pave the way for new and improved treatments for skin diseases.

Skin Immunity and Disease: A Dedicated Research Networking Program at the 18th International Symposium on Dendritic Cells

Grantee: Professor Elina Zuniga, University of California, San Diego, United States

Amount: DKK 277,889

Grant category: Research Networking

Year: 2026

Geography: USA

The 18th International Symposium on Dendritic Cells (DC2026) will take place on October 11-14, 2026, in San Diego, USA. This international meeting brings together scientists and clinicians studying dendritic cells: immune cells that help the body decide when to fight infection or limit unnecessary inflammation. In the skin, dendritic cells play a particularly important role. The skin is the body’s largest immune organ and is constantly exposed to microbes, allergens, and environmental stress. When dendritic cell function is disturbed, it can lead to skin diseases such as psoriasis, dermatitis, infection, and skin cancer. With support from the LEO Foundation, DC2026 will include a dedicated skin-focused program with a plenary session, poster presentations, and networking activities. Funding will also support early-career researchers, helping them share new discoveries and build collaborations that advance skin health. More information: https://www.dc2026sandiego.com/

SID Resident and Post Doc Retreat/Young Investigator Event

Grantee: Society for Investigative Dermatology (SID)

Amount: EUR 25,000

Grant category: Research Networking

Year: 2026

Geography: USA

The Resident and Post Doc Retreat is a conference hosted by the Society for Investigative Dermatology (SID) each year since 2001. The program format provides a protected space in which residents can interact with senior faculty and established investigators for the purpose of fostering attendees’ interest in academic research careers. The program is a combination of formal lectures and presentations, informal discussions, brainstorming sessions and social activities. The retreat is held at the time of the SID annual meeting, which allows attendees to establish connections with each other, and to other meeting attendees. These social networks foster collegiality, collaborations, and appreciation for the creative, multidisciplinary nature of science and other productive interactions.

Read more

VEGF-A as a therapeutic target in pemphigoid

Grantee: Kyle Amber, Associate Professor, Rush University Medical Center, United States

Amount: DKK 3,872,028

Grant category: Research Grants

Year: 2026

Geography: USA

Bullous pemphigoid (BP) is a serious blistering skin disease usually treated with long courses of steroids, which can cause major side effects. Despite advances in treatment, therapy for acute disease still relies heavily on prolonged high-dose oral corticosteroids. We found that a molecule called VEGF-A—known for driving inflammation—is much higher in the blood, and skin of people with BP. VEGF-A also rises alongside many other inflammatory signals. Early experiments in mice show that blocking VEGF-A can make the disease noticeably less severe. This project will test whether targeting VEGF-A can quickly reduce skin involvement in relevant models of pemphigoid. We will also study whether VEGF-A made specifically by skin cells is a key trigger of inflammation, and whether blocking VEGF-A in the skin (including with topical treatments) can help. The goal is to determine if VEGF-A could be a new, fast-acting, steroid-sparing treatment for BP.